HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in ISI Web of Science Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Request Reprints Citing Articles Citing Articles via ISI Web of Science (1) Citing Articles via Google Scholar Google Scholar Articles by Elkind, A. H. Articles by Ishkanian, G. Search for Related Content PubMed PubMed Citation Articles by Elkind, A. H. Articles by Ishkanian, G. Social Bookmarking                   What's this?

Pharmacokinetics of Frovatriptan in Adolescent Migraineurs

From the Elkind Headache Center, Mount Vernon, New York (Dr Elkind, Dr Ishkanian) and Vernalis Ltd, Wokingham, Berkshire, United Kingdom (Dr Wade).

Frovatriptan is a selective 5-HT_1B/1D receptor agonist available for acute treatment of migraine in adults (18 years and older). The objective of this study was to determine key pharmacokinetic parameters of frovatriptan in adolescent migraineurs after a single 2.5-mg oral dose and to compare these results with those from an earlier study completed in adults. Subjects were stratified by age (12-14 and 15-17 years) and gender, and serial blood and urine samples were collected over 48 hours. A total of 25 subjects (13 male, 12 female) completed the study. Pharmacokinetic profiles for adolescent subjects were similar to those observed in adults. The median t_max ranged from 2 (male subjects) to 3 (female subjects) hours. The AUC_0-24h and C_max were slightly lower in adolescent subjects as compared with adults. As seen in adults, AUC_0-24h and C_max values were approximately 2-fold higher in females than in their male counterparts (AUC mean range 40.5-59.8 ng•h/mL vs 21.2-23.5 ng•h/mL and C_max mean range 4.02-6.14 vs ng•h/mL 2.52-2.99 ng/mL, in female and male adolescent subjects, respectively). Elimination was biphasic, with an approximate terminal elimination half-life (t_1/2) between 12.2 and 25.5 hours. Renal clearance was similar in adolescents and adults, being somewhat higher in female than male subjects. Frovatriptan was well tolerated with no serious or treatment-related adverse effects. In addition, there were no clinically significant changes in safety parameters. Overall, the pharmacokinetic profile of frovatriptan in adolescents (12-17 years) is similar to that seen in adults, and dosing adjustments are unlikely to be needed.

Key Words: Frovatriptan • adolescents • pharmacokinetics • migraine

Address for reprints: Arthur H. Elkind, MD, Elkind Headache Center, 12 North 7th Avenue, Mount Vernon, NY 10550.

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this?